Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression.

Eggert T, Wolter K, Ji J, Ma C, Yevsa T, Klotz S, Medina-Echeverz J, Longerich T, Forgues M, Reisinger F, Heikenwalder M, Wang XW, Zender L, Greten TF.

Cancer Cell. 2016 Oct 10;30(4):533-547. doi: 10.1016/j.ccell.2016.09.003.

2.

EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.

Venugopalan A, Lee MJ, Niu G, Medina-Echeverz J, Tomita Y, Lizak MJ, Cultraro CM, Simpson RM, Chen X, Trepel JB, Guha U.

Oncotarget. 2016 Aug 23;7(34):54137-54156. doi: 10.18632/oncotarget.11021.

3.

Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs).

Alfaro C, Teijeira A, Oñate C, Pérez G, Sanmamed MF, Andueza MP, Alignani D, Labiano S, Azpilikueta A, Rodriguez-Paulete A, Garasa S, Fusco JP, Aznar A, Inogés S, De Pizzol M, Allegretti M, Medina-Echeverz J, Berraondo P, Perez-Gracia JL, Melero I.

Clin Cancer Res. 2016 Aug 1;22(15):3924-36. doi: 10.1158/1078-0432.CCR-15-2463. Epub 2016 Mar 8.

4.

NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.

Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, Terabe M, Kapoor V, ElGindi M, Han M, Thornton AM, Zhang H, Egger M, Luo J, Felsher DW, McVicar DW, Weber A, Heikenwalder M, Greten TF.

Nature. 2016 Mar 10;531(7593):253-7. doi: 10.1038/nature16969. Epub 2016 Mar 2.

5.

Hepatic myeloid-derived suppressor cells in cancer.

Medina-Echeverz J, Eggert T, Han M, Greten TF.

Cancer Immunol Immunother. 2015 Aug;64(8):931-40. doi: 10.1007/s00262-015-1736-y. Epub 2015 Jul 2. Review.

6.

Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells.

Medina-Echeverz J, Vasquez M, Gomar C, Ardaiz N, Berraondo P.

Cancer Immunol Immunother. 2015 Jun;64(6):717-25. doi: 10.1007/s00262-015-1681-9. Epub 2015 Mar 21.

PMID:
25795134
7.

The yin and yang of evasion and immune activation in HCC.

Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF.

J Hepatol. 2015 Jun;62(6):1420-9. doi: 10.1016/j.jhep.2015.02.038. Epub 2015 Feb 27. Review.

8.

Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.

Medina-Echeverz J, Ma C, Duffy AG, Eggert T, Hawk N, Kleiner DE, Korangy F, Greten TF.

Cancer Immunol Res. 2015 May;3(5):557-66. doi: 10.1158/2326-6066.CIR-14-0182. Epub 2015 Jan 30.

9.

Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner.

Kapanadze T, Medina-Echeverz J, Gamrekelashvili J, Weiss JM, Wiltrout RH, Kapoor V, Hawk N, Terabe M, Berzofsky JA, Manns MP, Wang E, Marincola FM, Korangy F, Greten TF.

Eur J Immunol. 2015 Apr;45(4):1148-58. doi: 10.1002/eji.201445093. Epub 2015 Feb 23.

10.

Tumor induced hepatic myeloid derived suppressor cells can cause moderate liver damage.

Eggert T, Medina-Echeverz J, Kapanadze T, Kruhlak MJ, Korangy F, Greten TF.

PLoS One. 2014 Nov 17;9(11):e112717. doi: 10.1371/journal.pone.0112717. eCollection 2014.

11.

Intravenous immunoglobulin promotes antitumor responses by modulating macrophage polarization.

Domínguez-Soto A, de las Casas-Engel M, Bragado R, Medina-Echeverz J, Aragoneses-Fenoll L, Martín-Gayo E, van Rooijen N, Berraondo P, Toribio ML, Moro MA, Cuartero I, Castrillo A, Sancho D, Sánchez-Torres C, Bruhns P, Sánchez-Ramón S, Corbí AL.

J Immunol. 2014 Nov 15;193(10):5181-9. doi: 10.4049/jimmunol.1303375. Epub 2014 Oct 17.

12.

Myeloid-derived cells are key targets of tumor immunotherapy.

Medina-Echeverz J, Aranda F, Berraondo P.

Oncoimmunology. 2014 Apr 15;3:e28398. eCollection 2014. Review.

13.

IFN-γ regulates survival and function of tumor-induced CD11b+ Gr-1high myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1.

Medina-Echeverz J, Haile LA, Zhao F, Gamrekelashvili J, Ma C, Métais JY, Dunbar CE, Kapoor V, Manns MP, Korangy F, Greten TF.

Eur J Immunol. 2014 Aug;44(8):2457-67. doi: 10.1002/eji.201444497. Epub 2014 Jun 16.

14.

Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases.

Medina-Echeverz J, Fioravanti J, Díaz-Valdés N, Frank K, Aranda F, Gomar C, Ardaiz N, Dotor J, Umansky V, Prieto J, Berraondo P.

PLoS One. 2014 May 5;9(5):e96799. doi: 10.1371/journal.pone.0096799. eCollection 2014.

15.

Eradication of liver-implanted tumors by Semliki Forest virus expressing IL-12 requires efficient long-term immune responses.

Quetglas JI, Rodriguez-Madoz JR, Bezunartea J, Ruiz-Guillen M, Casales E, Medina-Echeverz J, Prieto J, Berraondo P, Hervas-Stubbs S, Smerdou C.

J Immunol. 2013 Mar 15;190(6):2994-3004. doi: 10.4049/jimmunol.1201791. Epub 2013 Feb 11.

16.

Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy.

Ochoa MC, Fioravanti J, Duitman EH, Medina-Echeverz J, Palazon A, Arina A, Dubrot J, Alfaro C, Morales-Kastresana A, Murillo O, Hervas-Stubbs S, Prieto J, Berraondo P, Melero I.

PLoS One. 2012;7(12):e52370. doi: 10.1371/journal.pone.0052370. Epub 2012 Dec 21.

17.

How can chemoimmunotherapy best be used for the treatment of colon cancer?

Medina-Echeverz J, Berraondo P.

Immunotherapy. 2012 Dec;4(12):1787-90. doi: 10.2217/imt.12.124. No abstract available.

18.

Kinetic and dynamic computational model-based characterization of new proteins in mice: application to interferon alpha linked to apolipoprotein A-I.

Parra-Guillen ZP, Fioravanti J, Medina-Echeverz J, Gomar C, Ardaiz N, Troconiz IF, Berraondo P.

PLoS One. 2012;7(7):e42100. doi: 10.1371/journal.pone.0042100. Epub 2012 Jul 27.

19.
20.

The fusion protein of IFN-α and apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism.

Fioravanti J, Medina-Echeverz J, Ardaiz N, Gomar C, Parra-Guillén ZP, Prieto J, Berraondo P.

J Immunol. 2012 Apr 15;188(8):3988-92. doi: 10.4049/jimmunol.1101598. Epub 2012 Mar 14.

21.

A Semliki forest virus vector engineered to express IFNα induces efficient elimination of established tumors.

Quetglas JI, Fioravanti J, Ardaiz N, Medina-Echeverz J, Baraibar I, Prieto J, Smerdou C, Berraondo P.

Gene Ther. 2012 Mar;19(3):271-8. doi: 10.1038/gt.2011.99. Epub 2011 Jul 7.

PMID:
21734727
22.

Characterization of woodchuck apolipoprotein A-I: a new tool for drug delivery and identification of altered isoforms in the woodchuck chronic hepatitis model.

Fioravanti J, Gomar C, Medina-Echeverz J, Otano I, Benito A, Prieto J, González-Aseguinolaza G, Berraondo P.

J Med Virol. 2011 Jul;83(7):1221-9. doi: 10.1002/jmv.22104. Epub 2011 Apr 22.

PMID:
21520143
23.

Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties.

Fioravanti J, González I, Medina-Echeverz J, Larrea E, Ardaiz N, González-Aseguinolaza G, Prieto J, Berraondo P.

Hepatology. 2011 Jun;53(6):1864-73. doi: 10.1002/hep.24306. Epub 2011 May 2.

PMID:
21425312
24.

Scavenger receptor class B, type I: a promising immunotherapy target.

Fioravanti J, Medina-Echeverz J, Berraondo P.

Immunotherapy. 2011 Mar;3(3):395-406. doi: 10.2217/imt.10.104. Review.

PMID:
21395381
25.

Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells.

Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P.

J Immunol. 2011 Jan 15;186(2):807-15. doi: 10.4049/jimmunol.1001483. Epub 2010 Dec 8.

26.

Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice.

Gonzalez-Aparicio M, Alzuguren P, Mauleon I, Medina-Echeverz J, Hervas-Stubbs S, Mancheno U, Berraondo P, Crettaz J, Gonzalez-Aseguinolaza G, Prieto J, Hernandez-Alcoceba R.

Gut. 2011 Mar;60(3):341-9. doi: 10.1136/gut.2010.211722. Epub 2010 Sep 20.

Supplemental Content

Loading ...
Support Center